{"id":"benralizumab-prefilled-syringe","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nasopharyngitis"},{"rate":"5-10","effect":"Upper respiratory tract infection"},{"rate":"1-5","effect":"Injection site reactions"},{"rate":"1-5","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL1742991","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benralizumab targets interleukin-5 receptor alpha (IL-5Rα), a key receptor expressed on eosinophils and basophils. By blocking this receptor, the drug prevents IL-5 signaling and promotes antibody-dependent cellular cytotoxicity (ADCC), resulting in rapid depletion of these cells. This mechanism effectively reduces eosinophilic inflammation in conditions like severe eosinophilic asthma.","oneSentence":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:09.668Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT04191304","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-20","conditions":"Hypereosinophilic Syndrome","enrollment":134},{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT05006573","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-07-21","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":100},{"nctId":"NCT04565483","phase":"PHASE4","title":"Predictive Signature of Benralizumab Response","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2021-10-11","conditions":"Asthma; Eosinophilic, Severe Asthma","enrollment":220},{"nctId":"NCT05528913","phase":"PHASE2","title":"Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)","status":"WITHDRAWN","sponsor":"Charite University, Berlin, Germany","startDate":"2023-10","conditions":"Chronic Prurigo","enrollment":""},{"nctId":"NCT04543409","phase":"PHASE3","title":"A Study of Benralizumab in Patients With Eosinophilic Esophagitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-09-22","conditions":"Eosinophilic Esophagitis","enrollment":211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Transcriptomic"],"phase":"marketed","status":"active","brandName":"Benralizumab Prefilled Syringe","genericName":"Benralizumab Prefilled Syringe","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}